CG Oncology (CGON) Other Non-Current Liabilities (2023 - 2026)
CG Oncology's (CGON) quarterly Other Non-Current Liabilities came in at $1.5 million in Q1 2026, down 16.66% on a QoQ basis from $1.7 million in Q4 2025.
CG Oncology (CGON) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 3 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, changed N/A from the prior year.
- Other Non-Current Liabilities eased to $1.5 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.8 million in Q3 2025 to a low of $365000.0 in Q4 2023.
- A 3-year average of $1.8 million and a median of $1.6 million in 2025 frame the typical range for Other Non-Current Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Dec 31, 2023 | 365,000.00 |